About this item:

157 Views | 163 Downloads

Author Notes:

Correspondence: Field F. Willingham Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, 1365 Clifton Road NE Building B, Suite 1200, Atlanta, GA 30322, USA Tel: +1-404-778-3184, Fax: +1-404-778-2925 , E-mail: field.willingham@emory.edu

Conflicts of Interest:The authors have no financial conflicts of interest.

Subjects:

Research Funding:

This report was supported in part by a development grant from the Department of Medicine at Emory University School of Medicine.

Keywords:

  • Adenocarcinoma
  • Cryosurgery
  • Esophageal neoplasms

Long -term survival in stage IV esophageal adenocarcinoma with chemoradiation and serial endoscopic cryoablation

Tools:

Journal Title:

Clinical Endoscopy

Volume:

Volume 50, Number 5

Publisher:

, Pages 491-494

Type of Work:

Article | Final Publisher PDF

Abstract:

Esophageal cancer has a poor overall prognosis and is frequently diagnosed at a late stage. Conventional treatment for metastatic esophageal cancer involves chemotherapy and radiation. Local disease control plays a significant role in improving survival. Endoscopic spray cryotherapy is a novel modality that involves freezing and thawing to produce local ablation of malignant tissue via ischemic mechanisms. Spray cryotherapy has been shown to be effective, particularly for early T-stage, superficial esophageal adenocarcinomas. We present the case of a 72-year-old-male with locally recurrent stage IV esophageal adenocarcinoma and long-term survival of 7 years to date, with concurrent chemoradiation and serial cryoablation. He remains asymptomatic and continues to undergo chemotherapy and sequential cryoablation. The findings highlight the long-term safety and efficacy of cryotherapy in combination with chemoradiation, and suggest that cryoablation may have an additive role in the treatment of advanced stage esophageal adenocarcinoma.

Copyright information:

© 2017 Korean Society of Gastrointestinal Endoscopy.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Creative Commons License

Export to EndNote